GEOVAX LABS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
GEOVAX LABS, INC. (GOVX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-09.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2022-03-09
- GEOVAX LABS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- GEOVAX LABS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2020 was $65.00, a 76.62% decline from fiscal 2019.
- GEOVAX LABS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2019 was $278.00, a 49.36% decline from fiscal 2018.
- GEOVAX LABS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2018 was $549.00, a 25.92% increase from fiscal 2017.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-09 |
| 2020-12-31 | $65.00 10-K · filed 2022-03-09 |
| 2019-12-31 | $278.00 10-K · filed 2021-03-23 |
| 2018-12-31 | $549.00 10-K · filed 2020-03-24 |
| 2017-12-31 | $436.00 10-K · filed 2019-03-26 |
| 2016-12-31 | $2.01K 10-K · filed 2019-03-26 |
| 2015-12-31 | $2.91K 10-K · filed 2018-03-23 |
| 2014-12-31 | $1.73K 10-K · filed 2017-03-24 |
| 2013-12-31 | $3.14K 10-K · filed 2016-03-16 |
| 2012-12-31 | $2.67K 10-K · filed 2015-03-20 |
| 2011-12-31 | $4.22K 10-K · filed 2014-03-14 |
| 2010-12-31 | -$77.20K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B |